Elo Mutual Pension Insurance Co Makes New $2.03 Million Investment in Quest Diagnostics Incorporated $DGX

Elo Mutual Pension Insurance Co acquired a new stake in Quest Diagnostics Incorporated (NYSE:DGX) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,632 shares of the medical research company’s stock, valued at approximately $2,026,000.

A number of other hedge funds also recently added to or reduced their stakes in DGX. MTM Investment Management LLC acquired a new position in shares of Quest Diagnostics in the second quarter worth $29,000. True Wealth Design LLC grew its stake in Quest Diagnostics by 369.7% during the 3rd quarter. True Wealth Design LLC now owns 155 shares of the medical research company’s stock worth $30,000 after purchasing an additional 122 shares in the last quarter. AlphaQuest LLC increased its holdings in Quest Diagnostics by 18,400.0% during the 2nd quarter. AlphaQuest LLC now owns 185 shares of the medical research company’s stock worth $33,000 after purchasing an additional 184 shares during the period. First Horizon Corp acquired a new stake in Quest Diagnostics in the 3rd quarter valued at about $33,000. Finally, Rexford Capital Inc. purchased a new position in shares of Quest Diagnostics in the 2nd quarter valued at about $36,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Zacks raised multiyear and several quarterly targets — FY2026 to $10.57 (from $10.26), FY2027 to $11.42 and FY2028 to $12.54, and boosted multiple quarters (including Q2/Q3/Q4 2026 and several 2027 quarters). These upward revisions imply a stronger medium‑term earnings trajectory that can support a higher valuation. MarketBeat: DGX analyst notes
• Neutral Sentiment: Small/isolated tweaks — Q3 2027 was nudged +$0.01 to $2.90 and Q1 2026 was raised modestly to $2.37; these changes are too minor on their own to move sentiment meaningfully. MarketBeat: DGX analyst notes
• Negative Sentiment: Zacks trimmed its Q1 2027 estimate to $2.54 from $2.59, a near‑term cut that may weigh on sentiment and explain muted or negative intraday moves despite the larger upward revisions elsewhere. MarketBeat: DGX analyst notes

Insider Buying and Selling

In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 1,111 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $204.83, for a total transaction of $227,566.13. Following the transaction, the senior vice president owned 38,371 shares of the company’s stock, valued at $7,859,531.93. The trade was a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Catherine T. Doherty sold 1,433 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $204.83, for a total value of $293,521.39. Following the completion of the sale, the executive vice president owned 68,402 shares of the company’s stock, valued at approximately $14,010,781.66. This represents a 2.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 9,164 shares of company stock worth $1,872,363 in the last quarter. 8.16% of the stock is owned by insiders.

Quest Diagnostics Stock Down 0.1%

Shares of NYSE:DGX opened at $208.23 on Thursday. The firm has a 50 day simple moving average of $190.63 and a 200-day simple moving average of $185.47. Quest Diagnostics Incorporated has a twelve month low of $157.20 and a twelve month high of $213.50. The company has a current ratio of 1.04, a quick ratio of 0.96 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $22.88 billion, a PE ratio of 23.80, a P/E/G ratio of 2.69 and a beta of 0.66.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.35 by $0.07. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.57%. The firm had revenue of $2.81 billion for the quarter, compared to analyst estimates of $2.75 billion. During the same period last year, the business earned $2.23 EPS. Quest Diagnostics’s revenue for the quarter was up 7.1% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. On average, equities analysts predict that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Quest Diagnostics announced that its Board of Directors has approved a share repurchase plan on Tuesday, February 10th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 4.7% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its shares are undervalued.

Quest Diagnostics Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 20th. Investors of record on Monday, April 6th will be given a $0.86 dividend. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Monday, April 6th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.7%. Quest Diagnostics’s payout ratio is currently 36.57%.

Analyst Ratings Changes

DGX has been the topic of a number of recent research reports. Jefferies Financial Group upped their target price on shares of Quest Diagnostics from $215.00 to $220.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Weiss Ratings reissued a “buy (b-)” rating on shares of Quest Diagnostics in a research report on Monday, December 29th. Robert W. Baird set a $219.00 price objective on shares of Quest Diagnostics in a research report on Wednesday, February 11th. Mizuho boosted their target price on shares of Quest Diagnostics from $210.00 to $235.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Finally, Evercore set a $220.00 price target on Quest Diagnostics in a research note on Wednesday, February 11th. Eight research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $210.29.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.